Why do targeted agents not work in the adjuvant setting in colon cancer? (Q38062021)

28 August 2017

1 reference

title

Why do targeted agents not work in the adjuvant setting in colon cancer? (English)

1 reference

28 August 2017

Basak Oyan

1 reference

28 August 2017

publication date

1 October 2012

1 reference

Expert Review of Anticancer Therapy

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

1337-1345

1 reference

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Tumour dormancy: findings and hypotheses from clinical research on breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Src, chemoresistance and epithelial to mesenchymal transition: are they related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

The "seed and soil" hypothesis revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

Bone Morphogenic Protein-7 Induces Mesenchymal to Epithelial Transition in Adult Renal Fibroblasts and Facilitates Regeneration of Injured Kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.111

21 January 2018

Identifiers

DOI

10.1586/ERA.12.111

1 reference

28 August 2017

1 reference